Maria Di Bartolomeo

List of Publications by Citations

185 papers	6,941 citations	40 h-index	79 g-index
195 ext. papers	8,592 ext. citations	5.5 avg, IF	5.01 L-index

#	Paper	IF	Citations
185	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet, The*, **2018**, 392, 123-133	40	624
184	Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2010**, 303, 1729-37	27.4	586
183	Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. *Annals of Oncology*, **2009**, 20, 1842-7	10.3	419
182	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. *European Journal of Cancer*, **2015**, 51, 587-94	7.5	329
181	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. *Annals of Oncology*, **2009**, 20, 84-90	10.3	327
180	Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. *Cancer*, **1996**, 77, 402-8	6.4	224
179	Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. *Cancer*, **1999**, 86, 858-65	6.4	210
178	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncology, The*, **2019**, 20, 849-861	21.7	201
177	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. *Journal of Clinical Oncology*, **2019**, 37, 3392-3400	2.2	123
176	Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. *Cancer*, **2004**, 100, 279-87	6.4	122
175	5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. *Cancer*, **1998**, 83, 372-8	6.4	121
174	Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. *Journal of Clinical Oncology*, **1996**, 14, 2546-51	2.2	117
173	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 2414-2422	12.9	111
172	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 420-435	21.7	110
171	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. *Annals of Oncology*, **2015**, 26, 2092-7	10.3	110
170	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. *Cancer*, **1993**, 72, 3099-105	6.4	107
169	Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. *Annals of Oncology*, **2002**, 13, 299-307	10.3	100

168	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. *Clinical Cancer Research* , **2017**, 23, 5671-5678	12.9	91
167	Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. *Annals of Oncology*, **2002**, 13, 614-21	10.3	85
166	Resection versus transplantation for liver metastases from neuroendocrine tumors. *Transplantation Proceedings*, **2001**, 33, 1537-9	1.1	80
165	A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. *Annals of Oncology*, **1995**, 6, 77-9	10.3	74
164	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. *Cancer Discovery*, **2016**, 6, 963-71	24.4	71
163	Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. *British Journal of Cancer*, **1995**, 72, 1007-12	8.7	66
162	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. *Annals of Oncology*, **2014**, 25, 1373-1378	10.3	61
161	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. *Clinical Cancer Research*, **2018**, 24, 1082-1089	12.9	58
160	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *International Journal of Cancer*, **2016**, 139, 2859-2864	7.5	57
159	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. *Journal of Gastrointestinal Oncology*, **2017**, 8, 148-163	2.8	54
158	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2021**, 22, 779-789	21.7	53
157	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. *Annals of Oncology*, **2014**, 25, 404-8	10.3	51
156	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. *Cancer Treatment Reviews*, **2019**, 72, 45-55	14.4	51
155	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. *Critical Reviews in Oncology/Hematology*, **2015**, 96, 156-66	7	50
154	A review on biomarkers for prediction of treatment outcome in gastric cancer. *Anticancer Research*, **2013**, 33, 1257-66	2.3	48
153	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. *Annals of Oncology*, **2018**, 29, 1394-1401	10.3	47
152	Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. *PLoS ONE*, **2014**, 9, e108940	3.7	46
151	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Cancers*, **2019**, 11,	6.6	45

150	Toward the molecular dissection of peritoneal pseudomyxoma. *Annals of Oncology*, **2016**, 27, 2097-2103	10.3	45
149	Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. *International Journal of Radiation Oncology Biology Physics*, **1999**, 45, 285-9	4	43
148	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. *British Journal of Clinical Pharmacology*, **2015**, 80, 581-8	3.8	41
147	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. *Journal of Clinical Oncology*, **2018**, 36, 1478-1485	2.2	41
146	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. *European Journal of Cancer*, **2015**, 51, 800-7	7.5	40
145	Gastric cancer: Translating novels concepts into clinical practice. *Cancer Treatment Reviews*, **2019**, 79, 101889	14.4	39
144	Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. *Journal of Clinical Oncology*, **1995**, 13, 2613-9	2.2	39
143	Role of cMET in the development and progression of colorectal cancer. *International Journal of Molecular Sciences*, **2013**, 14, 18056-77	6.3	38
142	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2019**, 5, 1268-1275	13.4	37
141	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. *Oncologist*, **2014**, 19, 845-50	5.7	37
140	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. *Journal of Clinical Oncology*, **2019**, 37, 3099-3110	2.2	35
139	Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. *Annals of Oncology*, **2016**, 27, 2074-2081	10.3	33
138	Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. *British Journal of Cancer*, **2007**, 96, 439-44	8.7	33
137	Treatment of carcinoid syndrome with recombinant interferon alpha-2a. *Acta Oncologica*, **1993**, 32, 235-8	3.2	33
136	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. *British Journal of Clinical Pharmacology*, **2014**, 78, 1228-37	3.8	32
135	Pathological features as predictors of recurrence after radical resection of gastric cancer. *British Journal of Surgery*, **2006**, 93, 205-9	5.3	32
134	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. *Oncologist*, **2018**, 23, 1178-1187	5.7	31
133	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.. *New England Journal of Medicine*, **2022**, 386, 449-462	59.2	30

132	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. *Oncologist*, **2015**, 20, 1261-5	5.7	29
131	Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. *Annals of Oncology*, **2007**, 18, 1810-6	10.3	28
130	Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?. *Oncology*, **2013**, 84, 191-9	3.6	27
129	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Scientific Reports*, **2019**, 9, 2858	4.9	26
128	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. *Journal of Translational Medicine*, **2016**, 14, 125	8.5	26
127	Osteopontin, E-cadherin, and Ecatenin expression as prognostic biomarkers in patients with radically resected gastric cancer. *Gastric Cancer*, **2016**, 19, 412-420	7.6	25
126	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. *International Journal of Cancer*, **2015**, 137, 1467-74	7.5	25
125	Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line Wild-Type Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2018**, 24, 2276-2284	12.9	25
124	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. *Radiotherapy and Oncology*, **2015**, 117, 315-21	5.3	24
123	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. *Clinical Colorectal Cancer*, **2019**, 18, 125-132.e2	3.8	23
122	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. *Targeted Oncology*, **2018**, 13, 227-234	5	23
121	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. *Targeted Oncology*, **2014**, 9, 155-62	5	23
120	Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. *World Journal of Gastroenterology*, **2014**, 20, 4516-25	5.6	23
119	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. *Annals of Oncology*, **2018**, 29, 1800-1806	10.3	22
118	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. *British Journal of Cancer*, **2017**, 117, 347-352	8.7	22
117	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. *Cancer Biology and Therapy*, **2013**, 14, 1098-103	4.6	22
116	Role of MGMT as biomarker in colorectal cancer. *World Journal of Clinical Cases*, **2014**, 2, 835-9	1.6	21
115	Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. *Oncology*, **1995**, 52, 41-4	3.6	19

114	The landscape of d16HER2 splice variant expression across HER2-positive cancers. *Scientific Reports* , **2019**, 9, 3545	4.9	18
113	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. *Targeted Oncology*, **2016**, 11, 337-43	5	18
112	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. *Medical Oncology*, **2015**, 32, 182	3.7	18
111	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. *Journal of Clinical Oncology*	2.2	18
110	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. *Oncologist*, **2020**, 25, 803-809	5.7	17
109	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. *PLoS ONE*, **2014**, 9, e92147	3.7	17
108	Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. *Acta Oncologica* , **1993**, 32, 245-50	3.2	17
107	The Landscape of Actionable Gene Fusions in Colorectal Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	17
106	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. *Critical Reviews in Oncology/Hematology*, **2016**, 98, 24-8	7	16
105	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. *Journal of Clinical Oncology*, **2019**, 37, 66-66	2.2	15
104	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. *Oncologist*, **2019**, 24, 385-393	5.7	15
103	Gastrointestinal tract carcinoma in pediatric and adolescent age: The Italian TREP project experience. *Pediatric Blood and Cancer*, **2017**, 64, e26658	3	14
102	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. *Oncology*, **2019**, 97, 38-43	3.6	14
101	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. *Clinical Colorectal Cancer*, **2018**, 17, e457-e470	3.8	14
100	Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology. *British Journal of Cancer*, **1995**, 71, 1111-4	8.7	14
99	Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. *International Journal of Molecular Sciences*, **2015**, 16, 8884-95	6.3	13
98	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. *Critical Reviews in Oncology/Hematology*, **2015**, 95, 272-81	7	13
97	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. *Oncologist*, **2020**, 25, e460-e468	5.7	13

96	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocrine-Related Cancer*, **2018**, 25, 607-618	5.7	13
95	BRAF in metastatic colorectal cancer: the future starts now. *Pharmacogenomics*, **2015**, 16, 2069-81	2.6	13
94	Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. *Cancers*, **2014**, 6, 1753-68	6.6	13
93	Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. *Translational Oncology*, **2012**, 5, 155-9	4.9	13
92	Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. *Oncology*, **1996**, 53, 54-7	3.6	13
91	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. *European Journal of Cancer*, **2015**, 51, 473-481	7.5	12
90	Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. *European Journal of Cancer*, **1994**, 30A, 596-600	7.5	12
89	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clinical Colorectal Cancer*, **2020**, 19, 156-164	3.8	12
88	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. *Pharmacogenomics Journal*, **2019**, 19, 465-472	3.5	11
87	Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). *Clinical Colorectal Cancer*, **2019**, 18, 183-191.e3	3.8	11
86	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. *Targeted Oncology*, **2018**, 13, 567-582	5	11
85	A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. *Cancer*, **2012**, 118, 4132-8	6.4	11
84	Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. *European Journal of Cancer*, **1997**, 33, 687-90	7.5	11
83	Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. *Oncology*, **2006**, 71, 341-6	3.6	11
82	Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma. *Cancer*, **1996**, 78, 2087-93	6.4	11
81	Medical Treatment of Neuroendocrine Tumors. *Tumori*, **1993**, 79, 380-388	1.7	11
80	Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer. *Cancer*, **1998**, 83, 1136-41	6.4	10
79	Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition. *Tumori*, **2006**, 92, 379-383	1.7	10

78	Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. *Oncology*, **2004**, 66, 132-7	3.6	10
77	Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer. *Tumori*, **2016**, 102, e15-9	1.7	10
76	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. *Pharmacogenomics*, **2018**, 19, 1047-1068	2.6	9
75	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. *Oncology*, **2018**, 95, 344-352	3.6	9
74	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. *Clinical Colorectal Cancer*, **2017**, 16, e191-e198	3.8	9
73	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. *Cancer Research and Treatment*, **2017**, 49, 834-845	5.2	9
72	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. *BMC Cancer*, **2019**, 19, 283	4.8	8
71	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. *Oncology*, **2017**, 93, 279-286	3.6	8
70	TP53 mutations in advanced colorectal cancer: the dark side of the moon. *Oncology*, **2014**, 86, 289-94	3.6	8
69	Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2014**, 37, 545-9	2.7	8
68	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2020**, 26, 1017-1024	12.9	8
67	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. *Gastric Cancer*, **2021**, 1	7.6	8
66	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. *Clinical Colorectal Cancer*, **2019**, 18, e179-e190	3.8	7
65	Role of BAX for outcome prediction in gastrointestinal malignancies. *Medical Oncology*, **2013**, 30, 610	3.7	7
64	Acute Immune-Mediated Thrombocytopenia Due to Oxaliplatin Administration: A Case Report. *Tumori*, **2010**, 96, 154-156	1.7	7
63	FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. *British Journal of Cancer*, **1998**, 77, 1149-54	8.7	7
62	Raltitrexed plus Oxaliplatin in the Treatment of Metastatic Colorectal Cancer. *Tumori*, **2004**, 90, 186-191	1.7	7
61	TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. *Cancers*, **2021**, 13,	6.6	7

60	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. *Pharmacogenomics Journal*, **2017**, 17, 331-336	3.5	6
59	The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. *European Journal of Cancer*, **2019**, 111, 1-7	7.5	6
58	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. *European Journal of Cancer*, **2020**, 135, 230-239	7.5	6
57	Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. *Cancer Chemotherapy and Pharmacology*, **2009**, 64, 67-72	3.5	6
56	Capecitabine chemoradiation for rectal cancer after curative surgery. *Journal of Chemotherapy*, **2006**, 18, 85-9	2.3	6
55	The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. *Journal of Steroid Biochemistry and Molecular Biology*, **2000**, 75, 65-73	5.1	6
54	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
53	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. *European Journal of Cancer*, **2019**, 107, 164-174	7.5	6
52	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. *Clinical Cancer Research*, **2021**, 27, 3126-3140	12.9	6
51	Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. *Oncologist*, **2020**, 25, e928-e935	5.7	5
50	One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. *World Journal of Gastrointestinal Oncology*, **2020**, 12, 833-849	3.4	5
49	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors **2021**, 9,		5
48	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. *Clinical Colorectal Cancer*, **2019**, 18, 34-43.e6	3.8	5
47	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. *Oncologist*, **2020**, 25, 780-786	5.7	5
46	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. *European Journal of Surgical Oncology*, **2021**, 47, 4-10	3.6	5
45	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2021**, 144, 31-40	7.5	5
44	Nutritional Support Indications in Gastroesophageal Cancer Patients: From Perioperative to Palliative Systemic Therapy. A Comprehensive Review of the Last Decade. *Nutrients*, **2021**, 13,	6.7	5
43	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. *Gastric Cancer*, **2020**, 23, 1064-1074	7.6	4

42	A Modified Prognostic Score for Patients with Curatively Resected Gastric Cancer. *Tumori*, **2005**, 91, 221-226	1.7	4
41	Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression. *Transplant International*, **1994**, 7 Suppl 1, S409-11	3	4
40	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, 161-173	7.1	4
39	Neoadjuvant (re)chemoradiation for locally recurrent rectal cancer: Impact of anatomical site of pelvic recurrence on long-term results. *Surgical Oncology*, **2020**, 35, 89-96	2.5	4
38	Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. *Tumori*, **2019**, 105, 113-120	1.7	4
37	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. *Oncologist*, **2021**, 26, 302-309	5.7	4
36	A modified prognostic score for patients with curatively resected gastric cancer. *Tumori*, **2005**, 91, 221-6	1.7	4
35	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102583	2.2	4
34	Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab. *Medical Oncology*, **2012**, 29, 2838-41	3.7	3
33	Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. *European Journal of Cancer*, **1995**, 31A, 2426-7	7.5	3
32	Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma. *European Journal of Cancer*, **1993**, 29A, 1215-6	7.5	3
31	Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. *Cancers*, **2020**, 12,	6.6	3
30	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820927271	4.7	3
29	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. *Clinical Lung Cancer*, **2021**, 22, 161-169	4.9	3
28	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. *Supportive Care in Cancer*, **2021**, 29, 3971-3980	3.9	3
27	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 2505-2514	12.9	3
26	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. *Clinical and Translational Oncology*, **2013**, 15, 582-6	3.6	2
25	Feasibility of Intraportal Chemotherapy with Fluorouracil and Folinic Acid Immediately after Hepatic Resection for Colorectal Metastases. *Tumori*, **1995**, 81, 96-101	1.7	2

24	Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series.. *Annals of Surgical Oncology*, **2022**, 29, 3096	3.1	2
23	Ramucirumab as First-Line Therapy in Combination with Cisplatin and Fluoropyrimidine in Patients with Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINFALL): A Global, Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial. *SSRN Electronic Journal*,	1	2
22	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. *Tumori*, **2021**, 107, 150-159	1.7	2
21	Bilateral parotid gland metastases from gastric signet-ring cell carcinoma. *Tumori*, **2018**, 104, NP10-NP13	1.7	2
20	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.. *JCO Precision Oncology*, **2022**, 6, e2200015	3.6	2
19	In reply. *Oncologist*, **2015**, 20, e5	5.7	1
18	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. *Clinical Interventions in Aging*, **2015**, 10, 127-33	4	1
17	FOLFIRI with cetuximab or bevacizumab: FIRE-3. *Lancet Oncology, The*, **2014**, 15, e581	21.7	1
16	Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. *Drugs and Aging*, **2011**, 28, 83-91	4.7	1
15	Doxifluridine: Previous Experience and new Developments in the Treatment of Colorectal Cancer. *Tumori*, **1997**, 83, 87-89	1.7	1
14	Well-Differentiated Neuroendocrine Carcinoma of the Lung: A Case Report. *Tumori*, **1991**, 77, 282-284	1.7	1
13	ASO Visual Abstract: Impact of Surgical Margins on Overall Survival After Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series.. *Annals of Surgical Oncology*, **2022**, 29, 3111	3.1	1
12	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.. *Frontiers in Oncology*, **2022**, 12, 780716	5.3	1
11	Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.. *European Journal of Cancer*, **2022**, 166, 100-111	7.5	1
10	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. *Future Oncology*, **2019**, 15, 3015-3024	3.6	0
9	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. *Oncologist*, **2022**, 27, e29-e36	5.7	0
8	Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. *European Journal of Cancer*, **2021**, 148, 190-201	7.5	0
7	Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. *Future Oncology*, **2021**, 17, 2315-2324	3.6	0

6	Target therapies plus somatostatin analogs in NETs: a network meta-analysis. *Endocrine-Related Cancer*, **2021**, 28, 467-479	5.7	0
5	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. *JAMA Network Open*, **2022**, 5, e220290	10.4	0
4	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma.. *JCO Precision Oncology*, **2022**, 6, e2100472	3.6	0
3	Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. *Future Oncology*, **2021**, 17, 1749-1759	3.6	
2	Atypical Mutations in Metastatic Colorectal Cancer.. *JCO Precision Oncology*, **2019**, 3, 1-11	3.6	
1	Tumors of the Small Intestine, Colon, and Rectum. *Pediatric Oncology*, **2022**, 223-244	0.5	